{"name": "Acylin Therapeutics",
 "permalink": "acylin-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/acylin-therapeutics",
 "homepage_url": "http://www.acceleratorcorp.com/node/111",
 "blog_url": "",
 "blog_feed_url": "http://www.acceleratorcorp.com/news/accelerator",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2009,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "206-957-7300",
 "description": "",
 "created_at": "Thu Jan 20 05:44:20 UTC 2011",
 "updated_at": "Fri May 24 10:44:08 UTC 2013",
 "overview": "\u003Cp\u003EAcylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       51],
      "assets/images/resized/0024/5591/245591v1-max-150x150.jpg"],
     [[156,
       54],
      "assets/images/resized/0024/5591/245591v1-max-250x250.jpg"],
     [[156,
       54],
      "assets/images/resized/0024/5591/245591v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and Chief Business Officer",
    "person":
     {"first_name": "David",
      "last_name": "Schubert",
      "permalink": "david-schubert",
      "image":
       {"available_sizes":
         [[[149,
            110],
           "assets/images/resized/0026/6402/266402v1-max-150x150.jpg"],
          [[149,
            110],
           "assets/images/resized/0026/6402/266402v1-max-250x250.jpg"],
          [[149,
            110],
           "assets/images/resized/0026/6402/266402v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Controller and Vice President of Operations",
    "person":
     {"first_name": "Lindsay",
      "last_name": "Rayle",
      "permalink": "lindsay-rayle",
      "image":
       {"available_sizes":
         [[[149,
            110],
           "assets/images/resized/0026/5610/265610v1-max-150x150.jpg"],
          [[149,
            110],
           "assets/images/resized/0026/5610/265610v1-max-250x250.jpg"],
          [[149,
            110],
           "assets/images/resized/0026/5610/265610v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Janis",
      "last_name": "Naeve",
      "permalink": "janis-naeve",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/6412/266412v2-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6412/266412v2-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6412/266412v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Lee",
      "last_name": "Babiss",
      "permalink": "lee-babiss",
      "image":
       {"available_sizes":
         [[[110,
            110],
           "assets/images/resized/0026/6417/266417v1-max-150x150.jpg"],
          [[110,
            110],
           "assets/images/resized/0026/6417/266417v1-max-250x250.jpg"],
          [[110,
            110],
           "assets/images/resized/0026/6417/266417v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$4.4M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://onbiovc.com/acylin-therapeutics-inc-series-a-44m/",
    "source_description": "Acylin Therapeutics, Inc.: Series A $4.4M",
    "raised_amount": 4400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 1,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Alexandria Real Estate Equities",
         "permalink": "alexandria-real-estate-equities",
         "image":
          {"available_sizes":
            [[[150,
               52],
              "assets/images/resized/0005/2582/52582v2-max-150x150.jpg"],
             [[235,
               82],
              "assets/images/resized/0005/2582/52582v2-max-250x250.jpg"],
             [[235,
               82],
              "assets/images/resized/0005/2582/52582v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Amgen Ventures",
         "permalink": "amgen-ventures",
         "image":
          {"available_sizes":
            [[[150,
               28],
              "assets/images/resized/0023/2414/232414v2-max-150x150.jpg"],
             [[250,
               47],
              "assets/images/resized/0023/2414/232414v2-max-250x250.jpg"],
             [[450,
               84],
              "assets/images/resized/0023/2414/232414v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "ARCH Venture Partners",
         "permalink": "arch-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0003/6165/36165v2-max-150x150.png"],
             [[250,
               51],
              "assets/images/resized/0003/6165/36165v2-max-250x250.png"],
             [[300,
               62],
              "assets/images/resized/0003/6165/36165v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "OVP Venture Partners",
         "permalink": "ovp-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               63],
              "assets/images/resized/0003/0402/30402v1-max-150x150.png"],
             [[250,
               106],
              "assets/images/resized/0003/0402/30402v1-max-250x250.png"],
             [[272,
               116],
              "assets/images/resized/0003/0402/30402v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1616 Eastlake Avenue",
    "address2": "Suite 203",
    "zip_code": "98102",
    "city": "Seattle",
    "state_code": "WA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}